K 7259

Drug Profile

K 7259

Latest Information Update: 04 Sep 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kowa
  • Developer Kowa; Nonindustrial source
  • Class Anti-ischaemics; Neuroprotectants; Nootropics
  • Mechanism of Action Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cognition disorders; Ischaemic heart disorders; Neurological disorders

Most Recent Events

  • 09 Nov 1999 A preclinical study has been added to the Ischaemic Heart Disease pharmacodynamics section
  • 18 Jul 1997 A study has been added to the Ischaemic Heart Disease pharmacodynamics section
  • 13 Dec 1996 Preclinical development for Neurological disorders in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top